<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Specific allergen immunotherapy for the treatment of atopic eczema - Tam, H - 2016 | Cochrane Library</title> <meta content="Specific allergen immunotherapy for the treatment of atopic eczema - Tam, H - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008774.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Specific allergen immunotherapy for the treatment of atopic eczema - Tam, H - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008774.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008774.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Specific allergen immunotherapy for the treatment of atopic eczema" name="citation_title"/> <meta content="Herman Tam" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Moises A Calderon" name="citation_author"/> <meta content="National Heart and Lung Institute, Imperial College London" name="citation_author_institution"/> <meta content="Logan Manikam" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Helen Nankervis" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Ignacio García Núñez" name="citation_author"/> <meta content="Hospital Universitario Carlos Haya" name="citation_author_institution"/> <meta content="Hywel C Williams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Stephen Durham" name="citation_author"/> <meta content="National Heart and Lung Institute, Imperial College London" name="citation_author_institution"/> <meta content="Robert J Boyle" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="r.boyle@nhs.net" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008774.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/02/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008774.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008774.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008774.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Allergens [*therapeutic use]; Dermatitis, Atopic [*therapy]; Dermatophagoides farinae; Dermatophagoides pteronyssinus; Desensitization, Immunologic [*methods]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008774.pub2&amp;doi=10.1002/14651858.CD008774.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="uQyIsxpV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008774\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008774\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","pl","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008774.pub2",title:"Specific allergen immunotherapy for the treatment of atopic eczema",firstPublishedDate:"Feb 12, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008774.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008774.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008774.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008774.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008774.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008774.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008774.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008774.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008774.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008774.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6020 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008774.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/appendices#CD008774-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/table_n/CD008774StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/table_n/CD008774StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Specific allergen immunotherapy for the treatment of atopic eczema</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0002">Herman Tam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0003">Moises A Calderon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0004">Logan Manikam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0005">Helen Nankervis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0006">Ignacio García Núñez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0007">Hywel C Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0008">Stephen Durham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information#CD008774-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Robert J Boyle</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information/en#CD008774-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 February 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008774.pub2">https://doi.org/10.1002/14651858.CD008774.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008774-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008774-abs-0009">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008774-abs-0001" lang="en"> <section id="CD008774-sec-0001"> <h3 class="title" id="CD008774-sec-0001">Background</h3> <p>Specific allergen immunotherapy (SIT) is a treatment that may improve disease severity in people with atopic eczema (AE) by inducing immune tolerance to the relevant allergen. A high quality systematic review has not previously assessed the efficacy and safety of this treatment. </p> </section> <section id="CD008774-sec-0002"> <h3 class="title" id="CD008774-sec-0002">Objectives</h3> <p>To assess the effects of specific allergen immunotherapy (SIT), including subcutaneous, sublingual, intradermal, and oral routes, compared with placebo or a standard treatment in people with atopic eczema. </p> </section> <section id="CD008774-sec-0003"> <h3 class="title" id="CD008774-sec-0003">Search methods</h3> <p>We searched the following databases up to July 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (Issue 7, 2015), MEDLINE (from 1946), EMBASE (from 1974), LILACS (from 1982), Web of Science™ (from 2005), the Global Resource of EczemA Trials (GREAT database), and five trials databases. We searched abstracts from recent European and North American allergy meetings and checked the references of included studies and review articles for further references to relevant trials. </p> </section> <section id="CD008774-sec-0004"> <h3 class="title" id="CD008774-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of specific allergen immunotherapy that used standardised allergen extracts in people with AE. </p> </section> <section id="CD008774-sec-0005"> <h3 class="title" id="CD008774-sec-0005">Data collection and analysis</h3> <p>Two authors independently undertook study selection, data extraction (including adverse effects), assessment of risk of bias, and analyses. We used standard methodological procedures expected by Cochrane. </p> </section> <section id="CD008774-sec-0006"> <h3 class="title" id="CD008774-sec-0006">Main results</h3> <p>We identified 12 RCTs for inclusion in this review; the total number of participants was 733. The interventions included SIT in children and adults allergic to either house dust mite (10 trials), grass pollen, or other inhalant allergens (two trials). They were administered subcutaneously (six trials), sublingually (four trials), orally, or intradermally (two trials). Overall, the risk of bias was moderate, with high loss to follow up and lack of blinding as the main methodological concern. </p> <p>Our primary outcomes were 'Participant‐ or parent‐reported global assessment of disease severity at the end of treatment'; 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures'; and 'Adverse events, such as acute episodes of asthma or anaphylaxis'. SCORing Atopic Dermatitis (SCORAD) is a means of measuring the effect of atopic dermatitis by area (A); intensity (B); and subjective measures (C), such as itch and sleeplessness, which we used. </p> <p>For 'Participant‐ or parent‐reported global assessment of disease severity at the end of treatment', one trial (20 participants) found improvement in 7/9 participants (78%) treated with the SIT compared with 3/11 (27%) treated with the placebo (risk ratio (RR) 2.85, 95% confidence interval (CI) 1.02 to 7.96; P = 0.04). Another study (24 participants) found no difference: global disease severity improved in 8/13 participants (62%) treated with the SIT compared with 9/11 (81%) treated with the placebo (RR 0.75, 95% CI 0.45 to 1.26; P = 0.38). We did not perform meta‐analysis because of high heterogeneity between these two studies. The quality of the evidence was low. </p> <p>For 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures', two trials (184 participants) did not find that the SIT improved SCORAD part C (mean difference (MD) ‐0.74, 95% CI ‐1.98 to 0.50) or sleep disturbance (MD ‐0.49, 95% CI ‐1.03 to 0.06) more than placebo. For SCORAD part C itch severity, these two trials (184 participants) did not find that the SIT improved itch (MD ‐0.24, 95% CI ‐1.00 to 0.52). One other non‐blinded study (60 participants) found that the SIT reduced itch compared with no treatment (MD ‐4.20, 95% CI ‐3.69 to ‐4.71) and reduced the participants' overall symptoms (P &lt; 0.01), but we could not pool these three studies due to high heterogeneity. The quality of the evidence was very low. </p> <p>Seven trials reported systemic adverse reactions: 18/282 participants (6.4%) treated with the SIT had a systemic reaction compared with 15/210 (7.1%) with no treatment (RR 0.78, 95% CI 0.41 to 1.49; the quality of the evidence was moderate). The same seven trials reported local adverse reactions: 90/280 participants (32.1%) treated with the SIT had a local reaction compared with 44/204 (21.6%) in the no treatment group (RR 1.27, 95% CI 0.89 to 1.81). As these had the same study limitations, we deemed the quality of the evidence to also be moderate. </p> <p>Of our secondary outcomes, there was a significant improvement in 'Investigator‐ or physician‐rated global assessment of disease severity at the end of treatment' (six trials, 262 participants; RR 1.48, 95% CI 1.16 to 1.88). None of the studies reported our secondary outcome 'Parent‐ or participant‐rated eczema severity assessed using a published scale', but two studies (n = 184), which have been mentioned above, used SCORAD part C, which we included as our primary outcome 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures'. </p> <p>Our findings were generally inconclusive because of the small number of studies. We were unable to determine by subgroup analyses a particular type of allergen or a particular age or level of disease severity where allergen immunotherapy was more successful. We were also unable to determine whether sublingual immunotherapy was associated with more local adverse reactions compared with subcutaneous immunotherapy. </p> </section> <section id="CD008774-sec-0007"> <h3 class="title" id="CD008774-sec-0007">Authors' conclusions</h3> <p>Overall, the quality of the evidence was low. The low quality was mainly due to the differing results between studies, lack of blinding in some studies, and relatively few studies reporting participant‐centred outcome measures. We found limited evidence that SIT may be an effective treatment for people with AE. The treatments used in these trials were not associated with an increased risk of local or systemic reactions. Future studies should use high quality allergen formulations with a proven track record in other allergic conditions and should include participant‐reported outcome measures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008774-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008774-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008774-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008774-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008774-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008774-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008774-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008774-abs-0003" lang="en"> <h3>Specific allergy immunotherapy for the treatment of atopic eczema</h3> <p><b>Background</b> </p> <p>At least one in seven children and one in 50 adults suffer from atopic eczema, a skin condition characterised by an itchy red rash. People with atopic eczema are allergic to things in the environment, such as house dust mites, and exposure to what they are allergic to may make their eczema worse. Specific allergen immunotherapy is a treatment that involves a course of injections or drops under the tongue containing the substance to which a person is allergic. The treatment can reduce the severity of a person's allergy and may therefore be able to reduce symptoms of atopic eczema. We evaluated whether specific allergen immunotherapy was better or worse than a standard treatment or placebo at improving disease severity and symptoms as assessed by participants, parents, or investigators. </p> <p><b>Review question</b> </p> <p>Is specific allergen immunotherapy an effective treatment for people with atopic eczema?</p> <p><b>Study characteristics</b> </p> <p>The evidence is current to July 2015. We found 12 studies, with 733 participants, which included both children and adults. Studies were conducted in specialist allergy centres in nine countries. The duration of trials ranged from four months to three years. Immunotherapy was administered to the participants in four different ways. Allergen manufacturers funded seven of the 12 studies. </p> <p><b>Key results</b> </p> <p>We found no evidence from the studies in our review that SIT may be an effective treatment for atopic eczema, as rated by participants or parents for disease severity and symptoms. We found limited evidence that SIT may improve investigator‐rated disease severity. Immunotherapy did not cause any more harm than a standard treatment or placebo. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of the evidence was low. We downgraded quality mainly due to the differing results between studies, lack of blinding in some studies, and that relatively few studies reported outcomes relevant to patients. Future studies should use high quality allergen formulations with a proven track record in other allergic conditions and should include participant‐reported outcome measures. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008774-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-sec-0093">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-sec-0135">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008774-sec-0093"></div> <h3 class="title" id="CD008774-sec-0094">Implications for practice</h3> <section id="CD008774-sec-0094"> <p>We found limited evidence that specific allergy immunotherapy (SIT) provides a treatment benefit for people with atopic eczema (AE) compared with placebo or no treatment, but due to methodological concerns in the included studies, this form of treatment cannot be recommended for AE at present. </p> </section> <h3 class="title" id="CD008774-sec-0095">Implications for research</h3> <section id="CD008774-sec-0095"> <p>The evidence to date is inconclusive, so more trials are needed to clarify whether SIT is effective for the treatment of atopic eczema. Further large, well‐blinded randomised controlled trials that use modern high quality allergen formulations with a proven track record in other allergic conditions and also evaluate patient‐reported primary outcome measures are needed. If the treatment is found to be efficacious, identification of those most likely to benefit would be of great interest. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008774-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008774-sec-0022"></div> <div class="table" id="CD008774-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Specific allergen immunotherapy versus no immunotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Specific immunotherapy compared with no immunotherapy for atopic eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with atopic eczema and inhalant allergen sensitisation </p> <p><b>Settings:</b> specialist allergy centres in the UK (2 trials), Italy (3 trials), USA, Germany, Belgium, Poland, Columbia, and China </p> <p><b>Intervention:</b> specific allergen immunotherapy </p> <p><b>Comparison:</b> no immunotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No immunotherapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Specific allergen immunotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐ or parent‐reported global assessment of disease severity</b> </p> <p>Follow‐up: 6 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<sup>a</sup> <br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in 7/9 participants (78%) in the immunotherapy group and 3/11 participants (27%) in the placebo group (RR 2.85, 95% CI 1.02 to 7.96; P = 0.04 (<a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>)) </p> <p>8/13 participants (62%) in the immunotherapy group and 9/11 participants (81%) in the placebo group (RR 0.75, 95% CI 0.45 to 1.26; P = 0.38 (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>)) </p> <p>Due to unexplained statistical heterogeneity, we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐ or parent‐reported specific symptoms of eczema</b> </p> <p>Follow‐up: 12 to 18 months</p> <p>SCORAD part C measured as a combination of 2 Visual Analogue Scales (1 for itch, 1 for sleep disturbance), each on a scale from 0, no specific symptoms, to 10, maximum specific symptoms </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD part C score ranged across control groups from <b>3.07 to 5.29</b> </p> <p>The mean SCORAD part C sleep severity score ranged across control groups from <b>0.8 to 2.31</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD part C score in the immunotherapy group was on average <b>0.74 lower (95% CI ‐1.98 to 0.50)</b> </p> <p>The mean SCORAD part C sleep severity score in the immunotherapy group was on average <b>0.49 lower (95% CI ‐1.03 to 0.06)</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<sup>a</sup> </p> <p>(6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itch: SCORAD part C itch severity at the end of treatment: MD ‐0.24, 95% CI ‐1.00 to 0.52; I² = 0% for <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a> and <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a> </p> <p>Itch severity score: MD ‐4.20, 95% CI ‐3.69 to ‐4.71 for <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a> </p> <p>Due to unexplained statistical heterogeneity, we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events ‐ any systemic reaction</b> </p> <p>Follow‐up: 6 to 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.78</b> (0.41 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>492<sup>a</sup> <br/> (7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> <br/> (29 to 106) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> <br/> (67 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Investigator‐ or physician‐rated global assessment of disease severity</b> </p> <p>Follow‐up: 1 to 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.48</b> (1.16 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>286<sup>a</sup> </p> <p>(7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 10)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>697 per 1000</b> </p> <p>(546 to 885)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>778 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1151 per 1000</b> </p> <p>(903 to 1462)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐ or physician‐rated eczema severity using a published scale</b> </p> <p>Follow‐up: 12 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD score ranged across control groups from <b>26.7 to 32.6</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD score in the immunotherapy group was on average <b>5.79 lower (95% CI ‐7.92 to ‐3.66)</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<sup>a</sup> </p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant or parent‐rated eczema severity using a published scale</b> </p> <p>Follow‐up: 12 to 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184<sup>a</sup> <br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD part C used as the specific eczema symptom score (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR:</b> interquartile range; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SCORAD</b>: SCORing Atopic Dermatitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Assumed risks are based on the total control group risk across all included studies (medium risk population) and the included studies with the lowest (low risk population) and highest (high risk population) control group risks.<br/> <sup>a</sup>The number of total participants did not include those that were lost to follow up. The number of total participants and trials included those that contributed to narrative synthesis.<br/> <sup>b</sup>We downgraded the quality of the evidence by two levels because of unexplained heterogeneity (serious, ‐1) and imprecision (serious, ‐1). There was significant heterogeneity (I² = 83%) between the estimate of dichotomous effects in two studies (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a> and <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), and data were not pooled. The information size was small.<br/> <sup>c</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐1), imprecision (serious, ‐1), and unexplained heterogeneity (serious, ‐1). Two trials were non‐blinded (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). Moderate proportions of participants were not analysed (losses to follow up). The information size was small. Most subgroups of estimate of treatment effects were not significant, with high heterogeneity displayed by itch (I² = 98%). We did not pool data from all studies because of different symptoms and different scoring systems reported.<br/> <sup>d</sup>We downgraded the quality of the evidence by one level because of imprecision (serious, ‐1). The estimate of treatment effect relied largely on two studies (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). It is unclear whether the estimate obtained from a small number of adverse reactions to two different dust mite extracts can be generalised. Indeed, data from other populations suggest that specific allergen immunotherapy is generally associated with a small but significant risk of systemic adverse reactions.<br/> <sup>e</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐2) and imprecision (serious, ‐1). The estimate of treatment effect relied on two non‐blinded studies. The information size was small.<br/> <sup>f</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐2) and imprecision (serious, ‐1). Two studies were non‐blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small.<br/> <sup>g</sup>We downgraded the quality of the evidence by two levels because of study limitations (serious, ‐1) and imprecision (serious, ‐1). One study was non‐blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small. We did not include analyses of non‐published scales in this summary table. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008774-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-sec-0115">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD008774-sec-0023"></div> <p>We have listed unfamiliar terms in the glossary of terms in <a href="#CD008774-tbl-0002">Table 1</a>. </p> <div class="table" id="CD008774-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious, life‐threatening allergic reaction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fissuration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formation of tears in the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intradermally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Into the skin (dermis), below the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lichenification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thickening and hardening of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monovalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 kind of antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perennial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐lasting continually</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Photopheresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A form of apheresis and photodynamic therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Under the tongue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid‐filled cavities</p> </td> </tr> </tbody> </table> </div> <section id="CD008774-sec-0024"> <h3 class="title" id="CD008774-sec-0024">Description of the condition</h3> <p>Atopic eczema (AE) is a chronic inflammatory skin condition that affects 15% to 30% of children and 2% to 10% of adults world wide (<a href="./references#CD008774-bbs2-0104" title="OdhiamboJA , WilliamsHC , ClaytonTO , RobertsonCF , AsherMI , ISAAC Phase Three Study Group. Global variation in prevalence of eczema symptoms in children from ISAAC phase three. Journal of Allergy &amp; Clinical Immunology2009;124(6):1251‐8. [MEDLINE: 20004783] ">Odhiambo 2009</a>; <a href="./references#CD008774-bbs2-0111" title="WilliamsH , FlohrC . How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2006;118(1):209‐13. [PUBMED: 16815157] ">Williams 2006</a>). The terms 'atopic eczema' and 'atopic dermatitis' are synonymous. Severe itching and patches of dry inflamed skin in varying locations depending on the age of the person characterise this condition (<a href="./references#CD008774-bbs2-0079" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy2006;61(8):969‐987. [MEDLINE: 16867052] ">Akdis 2006</a>). In infants, AE is usually found on the cheeks, forehead, or scalp. In childhood, AE usually involves the hands, feet, wrists, ankles, and the creases of the elbows and backs of the knees (<a href="./references#CD008774-bbs2-0079" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy2006;61(8):969‐987. [MEDLINE: 16867052] ">Akdis 2006</a>). In adults, AE causes dry scaly patches and large plaques of thickened (lichenified) skin in the flexural folds; the face and neck; the upper arms and back; and the backs of the hands, feet, fingers, and toes (<a href="./references#CD008774-bbs2-0079" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy2006;61(8):969‐987. [MEDLINE: 16867052] ">Akdis 2006</a>). Strictly speaking, the term 'atopic eczema' "should only refer to individuals who have the physical features of eczema plus evidence of specific immunoglobulin E (IgE) antibodies to common environmental allergens such as house dust mite" (<a href="./references#CD008774-bbs2-0101" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy &amp; Clinical Immunology2004;113(5):832‐6. [MEDLINE: 15131563] ">Johansson 2004</a>). We have used this strict definition throughout this review unless we have specified otherwise. </p> <p>Several observations suggest that allergens may be important causes of atopic eczema. Firstly, direct exposure of the skin to environmental allergens, including perennial allergens like house dust mite, and seasonal allergens like pollen has been shown to increase the severity of atopic eczema (<a href="./references#CD008774-bbs2-0090" title="CapristoC , RomeiI , BonerAL . Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: Avoidance of indoor allergens. Allergy2004;59(Suppl 78):53‐60. [MEDLINE: 15245359] ">Capristo 2004</a>; <a href="./references#CD008774-bbs2-0106" title="PurvisDJ , ThompsonJM , ClarkPM , RobinsonE , BlackPN , WildCJ , et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. British Journal of Dermatology2005;152(4):742‐9. [MEDLINE: 15840107] ">Purvis 2005</a>; <a href="./references#CD008774-bbs2-0108" title="SchäferT , HeinrichJ , WjstM , AdamH , RingJ , WichmannHE . Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. Journal of Allergy &amp; Clinical Immunology1999;104(6):1280‐40. [MEDLINE: 10589013] ">Schäfer 1999</a>). Secondly, other diseases triggered by allergens are common in those with atopic eczema. For example, of those children who develop the condition during the first two years of life, an estimated 50% may develop asthma during subsequent years (<a href="./references#CD008774-bbs2-0110" title="WarnerJO , ETAC Study Group, Early Treatment of the Atopic Child. A double‐blinded, randomized, placebo‐controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' post‐treatment follow‐up. Journal of Allergy &amp; Clinical Immunology2001;108(6):929‐37. [MEDLINE: 11742270] ">Warner 2001</a>). Finally, those with more severe AE have an increased risk of asthma and allergic rhinitis (<a href="./references#CD008774-bbs2-0097" title="GustafssonD , SjöbergO , FoucardT . Development of allergies and asthma in infants and young children with atopic dermatitis ‐ A prospective follow‐up to 7 years of age. Allergy2000;55(3):240‐5. [MEDLINE: 10753014] ">Gustafsson 2000</a>; <a href="./references#CD008774-bbs2-0100" title="IlliS , vonMutiusE , LauS , NickelR , GrüberC , NiggemannB , et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. Journal of Allergy &amp; Clinical Immunology2004;113(5):925‐31. [MEDLINE: 15131576] ">Illi 2004</a>). </p> <p>Despite the current available topical treatment with emollients; corticosteroids; calcineurin inhibitors; and other treatments, such as antibiotics, people with atopic eczema often cannot keep their condition completely under control. In some cases, the medications used can cause more harm than benefit (<a href="./references#CD008774-bbs2-0079" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy2006;61(8):969‐987. [MEDLINE: 16867052] ">Akdis 2006</a>). Therefore, considering the atopic background of the disease and its possible correlation with allergen‐triggering factors, some other types of treatment have been proposed, which include specific allergen immunotherapy (SIT) (<a href="./references#CD008774-bbs2-0093" title="DarsowU . Allergen‐specific immunotherapy for atopic eczema: updated. Current Opinion in Allergy &amp; Clinical Immunology2012;12(6):665‐9. [PUBMED: 22918221] ">Darsow 2012</a>). </p> </section> <section id="CD008774-sec-0025"> <h3 class="title" id="CD008774-sec-0025">Description of the intervention</h3> <p>Specific allergen immunotherapy (SIT) is a treatment for allergic disease that involves the administration of an allergen in high doses in order to induce immune tolerance to that allergen and relieve symptoms (<a href="./references#CD008774-bbs2-0087" title="CalderonMA , AlvesB , JacobsonM , HurwitzB , SheikhA , DurhamS . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2] ">Calderon 2007</a>). For example, in people with hay fever who are allergic to grass pollen, SIT may involve treatment with injections, drops, or tablets of grass pollen over a period of months in order to relieve symptoms (<a href="./references#CD008774-bbs2-0087" title="CalderonMA , AlvesB , JacobsonM , HurwitzB , SheikhA , DurhamS . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2] ">Calderon 2007</a>; <a href="./references#CD008774-bbs2-0112" title="WilsonDR , LimaMT , DurhamSR . Sublingual immunotherapy for allergic rhinitis: Systematic review and meta‐analysis. Allergy2005;60(1):4‐12. [MEDLINE: 15575924] ">Wilson 2005</a>). Specific allergen immunotherapy is the only treatment shown to provide longer‐term benefit in allergic diseases after treatment has stopped (<a href="./references#CD008774-bbs2-0095" title="DurhamSR , WalkerSM , VargaEM , JacobsonMR , O'BrienF , NobleW , et al. Long‐term clinical efficacy of grass‐pollen immunotherapy. New England Journal of Medicine1999;341(7):468‐75. [MEDLINE: 10441602] ">Durham 1999</a>). It has been shown to be an effective treatment for allergic rhinitis and allergic asthma, although the treatment carries a risk of severe allergic reaction (<a href="./references#CD008774-bbs2-0087" title="CalderonMA , AlvesB , JacobsonM , HurwitzB , SheikhA , DurhamS . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2] ">Calderon 2007</a>; <a href="./references#CD008774-bbs2-0091" title="Committee of the Safety of Medicine. CSM update: Desensitising vaccines. British Medical Journal Clinical Research Ed.1986;293(6552):948. [MEDLINE: 20742706] ">CSM report 1986</a>; <a href="./references#CD008774-bbs2-0112" title="WilsonDR , LimaMT , DurhamSR . Sublingual immunotherapy for allergic rhinitis: Systematic review and meta‐analysis. Allergy2005;60(1):4‐12. [MEDLINE: 15575924] ">Wilson 2005</a>). </p> </section> <section id="CD008774-sec-0026"> <h3 class="title" id="CD008774-sec-0026">How the intervention might work</h3> <p>Specific allergen immunotherapy works by inducing changes in the immune response to the relevant allergen, so that in diseases caused by an abnormal response to that allergen, there may be an improvement in symptoms (<a href="./references#CD008774-bbs2-0080" title="AllamJP , NovakN . The pathophysiology of atopic eczema. Clinical &amp; Experimental Dermatology2006;31(1):89‐93. [MEDLINE: 16309494] ">Allam 2006</a>). The specific immune changes caused by SIT include an increase in activity of suppressive components of the immune system (regulatory T cells) and an increase in antibodies (immunoglobulin G (IgG) antibodies) to the allergen (<a href="./references#CD008774-bbs2-0085" title="BussmannC , MaintzL , HartJ , AllamJP , VrtalaS , ChenKW , et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: A pilot study. Clinical &amp; Experimental Allergy2007;37(9):1277‐85. [MEDLINE: 17845407] ">Bussmann 2007</a>; <a href="./references#CD008774-bbs2-0086" title="BussmannC , BieberT , NovakN . Systemic therapeutic options for severe atopic dermatitis. Journal der Deutschen Dermatologischen Gesellschaft2009;7(3):205‐19. [MEDLINE: 18759739] ">Bussmann 2009</a>; <a href="./references#CD008774-bbs2-0103" title="MaintzL , NovakN . Getting more and more complex: The pathophysiology of atopic eczema. European Journal of Dermatology2007;17(4):267‐83. [MEDLINE: 17540632] ">Maintz 2007</a>). The presence of allergic sensitisation in those with AE and the relationship between AE and other allergic diseases suggest that allergic immune responses are an important part of the disease process in AE (<a href="./references#CD008774-bbs2-0097" title="GustafssonD , SjöbergO , FoucardT . Development of allergies and asthma in infants and young children with atopic dermatitis ‐ A prospective follow‐up to 7 years of age. Allergy2000;55(3):240‐5. [MEDLINE: 10753014] ">Gustafsson 2000</a>; <a href="./references#CD008774-bbs2-0100" title="IlliS , vonMutiusE , LauS , NickelR , GrüberC , NiggemannB , et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. Journal of Allergy &amp; Clinical Immunology2004;113(5):925‐31. [MEDLINE: 15131576] ">Illi 2004</a>; <a href="./references#CD008774-bbs2-0110" title="WarnerJO , ETAC Study Group, Early Treatment of the Atopic Child. A double‐blinded, randomized, placebo‐controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' post‐treatment follow‐up. Journal of Allergy &amp; Clinical Immunology2001;108(6):929‐37. [MEDLINE: 11742270] ">Warner 2001</a>). It is therefore plausible that SIT might be able to reduce symptoms in people with AE by inhibiting abnormal immune responses to allergens. </p> </section> <section id="CD008774-sec-0027"> <h3 class="title" id="CD008774-sec-0027">Why it is important to do this review</h3> <p>Specific allergen immunotherapy is a disease‐modifying treatment that reduces symptoms in people with other allergic conditions: allergic rhinitis, allergic conjunctivitis, and asthma (<a href="./references#CD008774-bbs2-0078" title="AbramsonMJ , PuyRM , WeinerJM . Allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD001186.pub2] ">Abramson 2003</a>; <a href="./references#CD008774-bbs2-0087" title="CalderonMA , AlvesB , JacobsonM , HurwitzB , SheikhA , DurhamS . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2] ">Calderon 2007</a>; <a href="./references#CD008774-bbs2-0092" title="DahlR , KappA , ColomboG , deMonchyJG , RakS , EmmingerW , et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. Journal of Allergy &amp; Clinical Immunology2006;118(2):434‐40. [PUBMED: 16890769 ] ">Dahl 2006</a>; <a href="./references#CD008774-bbs2-0094" title="DidierA , MallingHJ , WormM , HorakF , JägerS , MontagutA , et al. Optimal dose, efficacy and safety of once‐daily sublingual immunotherapy with a 5‐grass pollen tablet for seasonal allergic rhinitis. Journal of Allergy &amp; Clinical Immunology2007;120(6):1338‐45. [PUBMED: 17935764 ] ">Didier 2007</a>; <a href="./references#CD008774-bbs2-0105" title="PenagosM , PassalacquaG , CompalatiE , Baena‐CagnaniCE , OrozcoS , PedrozaA , et al. Meta‐analysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest2008;133(3):599‐609. [PUBMED: 17951626 ] ">Penagos 2008</a>). Hence, SIT might be potentially effective in reducing AE. An evaluation of its effects on skin manifestations in the context of randomised controlled trials could provide an alternative treatment for people with AE. </p> <p>The plans for this review were published as a protocol 'Specific allergen immunotherapy for the treatment of atopic eczema' (<a href="./references#CD008774-bbs2-0088" title="CalderonMA , BoyleRJ , NankervisH , García NúñezI , WilliamsHC , DurhamS . Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database of Systematic Reviews2010, Issue 10. [DOI: 10.1002/14651858.CD008774] ">Calderon 2010</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008774-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-sec-0120">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008774-sec-0028"></div> <p>To assess the effects of specific allergen immunotherapy (SIT), including subcutaneous, sublingual, intradermal, and oral routes, compared with placebo or a standard treatment in people with atopic eczema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008774-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-sec-0121">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008774-sec-0029"></div> <section id="CD008774-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008774-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD008774-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults and children with atopic eczema (AE) and allergic sensitisation to an inhalant or food allergen. "Allergy needed to be proven using an objective test such as a positive skin prick test or high circulating levels of allergen‐specific IgE antibody detected by a specific blood test for allergy called the radioallergosorbent test. Trials focusing on allergic rhinitis or asthma without eczema were excluded" (<a href="./references#CD008774-bbs2-0089" title="CalderonMA , PenagosM , SheikhA , CanonicaGW , DurhamS . Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD007685.pub2] ">Calderon 2011</a>). Where trials included participants with and without AE, we only included the trial if the results for the participants with AE were separately reported. </p> </section> <section id="CD008774-sec-0033"> <h4 class="title">Types of interventions</h4> <p>High‐dose immunotherapy with standardised allergen extracts for single allergen or mixed allergens administered by the sublingual (under the tongue), subcutaneous (under the skin), intradermal (into the skin), or oral route compared with placebo or a standard treatment, such as emollients, topical corticosteroids, or topical calcineurin inhibitors. We considered all appropriate allergens at all doses and all durations of treatment. </p> </section> <section id="CD008774-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD008774-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008774-list-0001"> <li> <p>Participant‐ or parent‐reported global assessment of disease severity at the end of treatment, i.e. the proportion with good or excellent improvement at this time as reported in the trials (whether treatment was given for one, two, or three years, or other duration). </p> </li> <li> <p>Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures such as itch or sleep disturbance (SCORing Atopic Dermatitis (SCORAD) part C). </p> </li> <li> <p>Adverse events, such as acute episodes of asthma or anaphylaxis.</p> </li> </ol> </p> </section> <section id="CD008774-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008774-list-0002"> <li> <p>Investigator‐ or physician‐rated global assessment of disease severity at the end of treatment, i.e. the proportion with good or excellent improvement at this time as reported in the trials (whether treatment was given for one, two, or three years, or other duration). </p> </li> <li> <p>Parent‐ or participant‐rated eczema severity assessed using a published scale (e.g. Patient Oriented Eczema Measure (POEM)). </p> </li> <li> <p>Investigator‐ or physician‐rated eczema severity assessed using a published scale (e.g. SCORAD). </p> </li> <li> <p>Use of other medication for treatment of eczema during the intervention period (e.g. topical/systemic corticosteroids, calcineurin inhibitors, or oral antihistamines). </p> </li> <li> <p>Validated eczema‐related quality of life scores (e.g. Dermatitis Family Impact Questionnaire, Children's Dermatology Life Quality Index) (<a href="./references#CD008774-bbs2-0102" title="Lewis‐JonesMS , FinlayAY . The Children's Dermatology Life Quality Index (CDLQI): Initial validation and practical use. British Journal of Dermatology1995;132(6):942‐9. [MEDLINE: 7662573] ">Lewis‐Jones 1995</a>). </p> </li> </ol> </p> </section> </section> </section> <section id="CD008774-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD008774-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 21 July 2015:</p> <p> <ul id="CD008774-list-0003"> <li> <p>the Cochrane Skin Group Specialised Register using the terms '(dermatitis or eczema) and (immuno* or allerg*)'; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 7, in the Cochrane Library using the search strategy in <a href="./appendices#CD008774-sec-0099">Appendix 1</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD008774-sec-0100">Appendix 2</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD008774-sec-0101">Appendix 3</a>; </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD008774-sec-0102">Appendix 4</a>; </p> </li> <li> <p>the Global Resource of EczemA Trials. Centre of Evidence Based Dermatology, accessed at <a href="http://www.greatdatabase.org.uk" target="_blank">www.greatdatabase.org.uk</a>, using the terms 'immuno* or allerg*' in the title or keywords of records and restricting to included studies only; and </p> </li> <li> <p>Web of Science™ (from 2005) using the strategy in <a href="./appendices#CD008774-sec-0103">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD008774-sec-0039"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers up to 3 August 2015 using the terms 'immunotherapy and (eczema or dermatitis)'. </p> <p> <ul id="CD008774-list-0004"> <li> <p>The International Standard Randomised Controlled Trial Number (ISRCTN) registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> <li> <p>The Ongoing Skin Trials Register (<a href="http://www.nottingham.ac.uk/ongoingskintrials" target="_blank">www.nottingham.ac.uk/ongoingskintrials</a>). </p> </li> </ul> </p> </section> </section> <section id="CD008774-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We created a database of first and last names of authors of potentially eligible studies and searched the Science Citation Index Expanded (SCI‐EXPANDED, 1945 to the present) using these names in order to identify further relevant studies. </p> <section id="CD008774-sec-0041"> <h5 class="title">Reference lists</h5> <p>We checked the bibliographies of each included study and of published reviews for further reports of relevant trials. </p> </section> <section id="CD008774-sec-0042"> <h5 class="title">Correspondence</h5> <p>We contacted the primary author of each included study to identify additional published and unpublished studies. We contacted allergen immunotherapy product manufacturers to request details of published or unpublished studies of allergen immunotherapy that included eczema as an outcome measure. </p> </section> <section id="CD008774-sec-0043"> <h5 class="title">Conference proceedings</h5> <p>We searched the abstracts of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma &amp; Immunology meetings from 2010 to 2015. </p> </section> </section> </section> <section id="CD008774-sec-0044"> <h3 class="title" id="CD008774-sec-0044">Data collection and analysis</h3> <p>Some parts of the methods section of this review uses text that was originally published in other Cochrane Reviews co‐authored by RB and MC (predominantly <a href="./references#CD008774-bbs2-0084" title="BoyleRJ , ElremeliM , HockenhullJ , CherryMG , BulsaraMK , DanielsM , et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD008838.pub2] ">Boyle 2012</a> and <a href="./references#CD008774-bbs2-0089" title="CalderonMA , PenagosM , SheikhA , CanonicaGW , DurhamS . Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD007685.pub2] ">Calderon 2011</a>). We included a 'Summary of findings' table where we used the Grading of Recommendations Assessment, Development and Education (GRADE) approach to assess the quality of the evidence for the primary and secondary outcomes. </p> <section id="CD008774-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Two authors, RB and MC or HT, independently checked titles and abstracts identified from the searches, looked at the full text of all studies of possible relevance for assessment, and decided which trials met the inclusion criteria. The authors resolved any disagreements by discussing issues with each other, and the planned recourse to a third author (HN) for arbitration did not prove necessary. We sought further information from trial authors when needed to confirm eligibility. </p> </section> <section id="CD008774-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two authors, RB and HT or LM, independently extracted data from included trials and entered data into a specially designed data extraction sheet, and the authors met to compare results. MC, RB, and HT wrote to all authors to request additional information as required. Two authors, RB and HT or LM, entered the data into Review Manager (RevMan). </p> </section> <section id="CD008774-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed and documented the risk of bias in the included studies by concentrating on the following six parameters to assess quality: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias as specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008774-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org., Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Three authors, RB, HT, and HN, independently assessed risk of bias: we were not masked to study details. We met to resolve any disagreements, and the planned recourse to a fourth author, MC, for arbitration did not prove necessary. </p> <p>The 'Risk of bias' tables, which are part of the '<a href="./references#CD008774-sec-0112" title="">Characteristics of included studies</a>' tables, addressed each domain for each study. </p> </section> <section id="CD008774-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous data, we calculated individual and pooled statistics as mean differences (MD) where studies used the same outcome measure and reported them with a 95% confidence interval (CI) where possible. For dichotomous outcomes, we expressed results as a risk ratio (RR) with 95% CI, where possible. We were unable to express the result for dichotomous outcomes as number needed to treat (NNT) as we had originally planned. </p> </section> <section id="CD008774-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to analyse cross‐over trials through the use of techniques appropriate for paired designs and data from parallel trials and cross‐over trials as separate subgroups, since cross‐over studies may not be appropriate for immunotherapy studies. Our search did not identify any cross‐over trials. </p> <p>We planned to list non‐randomised controlled studies but did not discuss them further because we did not identify significant studies or data from non‐randomised controlled studies. </p> <p>Where studies reported more than one active intervention, we planned to combine the two active interventions and analyse them together, but we included no trials with more than one eligible active intervention. Where studies reported non‐parametric statistics, we planned to include these in meta‐analyses where possible, following the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008774-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org., Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD008774-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors when a paper did not present details about study design or descriptive statistics for outcomes (mean, standard deviation (SD)). If the authors did not respond within a reasonable time (six to eight weeks) to at least two separate written requests for information, we conducted the review based on available information. </p> </section> <section id="CD008774-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to test for heterogeneity and assumed substantial statistical heterogeneity if the I² was greater than 50% (<a href="./references#CD008774-bbs2-0098" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. [MEDLINE: 12111919] ">Higgins 2002</a>). We used sensitivity or subgroup analysis to explore any statistical or clinical heterogeneity (see below). Quantitative analyses of outcomes were, wherever possible, on an intention‐to‐treat basis, i.e. participants were evaluated in the groups to which they were randomised, rather than according to the actual treatment that they received. </p> <p>We gave consideration to the appropriateness of meta‐analysis in the presence of significant clinical or statistical heterogeneity and used a random‐effects model. </p> </section> <section id="CD008774-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use funnel plots to assess publication bias graphically (if there were sufficient included studies) and Begg and Egger tests to assess it statistically (<a href="./references#CD008774-bbs2-0083" title="BeggCB , MazumdarM . Operating characteristics of a rank correlation test for publication bias. Biometrics1994;50(4):1088‐101. [MEDLINE: 7786990] ">Begg 1994</a>; <a href="./references#CD008774-bbs2-0096" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>); however, we did not have a sufficient number of included studies. </p> </section> <section id="CD008774-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We planned to combine appropriate data from individual studies in a meta‐analysis only if heterogeneity measured by I² was less than 75% with the use of a random‐effects model. Where meta‐analyses were not applicable, we used a narrative synthesis of outcomes from relevant studies. </p> </section> <section id="CD008774-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned five a priori subgroup analyses.</p> <p> <ol id="CD008774-list-0005"> <li> <p>Immunotherapy type: sublingual and subcutaneous.</p> </li> <li> <p>Allergen type: seasonal inhalant, perennial inhalant, food, and microbial.</p> </li> <li> <p>Age of participants: up to four years, five to 11, 12 to 17, and 18 or over.</p> </li> <li> <p>Immunotherapy regimens to be subdivided empirically into low, intermediate, and high dose therapy according to content of major allergen per dose (e.g. <i>Phleum</i> p5 for grass, Bet v1 for birch pollen, Fel d1 for cat, etc.): </p> <ol id="CD008774-list-0006"> <li> <p>for subcutaneous immunotherapy, content of major allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11 mcg per four‐ to six‐weekly maintenance injection doses; and </p> </li> <li> <p>for sublingual immunotherapy, content of major allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11 mcg per daily maintenance sublingual dose (or equivalent if taken less frequently). </p> </li> </ol> </li> <li> <p>Severity of AE at randomisation: mild (SCORAD mean objective score of 0 to 15), moderate (SCORAD mean objective score of 16 to 40), and severe (SCORAD mean objective score of greater than 40). </p> </li> </ol> </p> </section> <section id="CD008774-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake sensitivity analysis for the allocation of missing data by best and worst case analysis. If we had found significant heterogeneity between studies, we planned to explore possible reasons for this, which would have included risk of bias in the included studies. However, we did not perform posthoc sensitivity analyses because of the small number of studies that contributed to meta‐analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008774-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008774-sec-0056"></div> <section id="CD008774-sec-0057"> <h3 class="title">Description of studies</h3> <p>See the '<a href="./references#CD008774-sec-0112" title="">Characteristics of included studies</a>', '<a href="./references#CD008774-sec-0113" title="">Characteristics of excluded studies</a>', 'Characteristics of studies awaiting classification', and '<a href="./references#CD008774-sec-0114" title="">Characteristics of ongoing studies</a>' tables. </p> <section id="CD008774-sec-0058"> <h4 class="title">Results of the search</h4> <p>The search identified 1550 references from electronic databases and six additional reports from other sources (three from screening references of review articles and three from ongoing trials registries), which gave a total of 1556 records (see the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow diagram in <a href="#CD008774-fig-0001">Figure 1</a>). We excluded 1465 references based on titles and abstracts. MC or HT and RB selected 91 records for which they screened the full text. We excluded 64 records and listed one as an ongoing study. Overall, 26 reports of 12 separate studies met the inclusion criteria (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>). We contacted the authors of all of the 12 included trials for original data and clarification of methods; we received further details from the authors or their collaborators for four trials (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>). </p> <div class="figure" id="CD008774-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD008774-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD008774-sec-0059"> <h4 class="title">Included studies</h4> <p>We included 12 studies, with a total of 733 participants.</p> <section id="CD008774-sec-0060"> <h5 class="title">Setting</h5> <p>Studies were conducted in specialist allergy centres in the UK (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), Italy (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>), the USA (<a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>), Germany (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>), Belgium (<a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>), Poland (<a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>), Columbia (<a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), Mexico (<a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>), and China (<a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). </p> </section> <section id="CD008774-sec-0061"> <h5 class="title">Participants</h5> <p>Two trials studied adults (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>), six studied children (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), and four studied both children and adults (<a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). Ten studies were restricted to people allergic to <i>Dermatophagoides pteronyssinus</i> or <i>Dermatophagoides farinae</i> (house dust mites) or both (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), one study was restricted to people allergic to house dust mites or grass pollen (<a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>), and one study was restricted to people allergic to a group of unspecified inhalant antigens (<a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>). </p> </section> <section id="CD008774-sec-0062"> <h5 class="title">Interventions</h5> <p>The 12 included studies were all of specific allergen immunotherapy (SIT). Of these, six trials studied subcutaneous immunotherapy (SCIT) (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), four studied sublingual immunotherapy (SLIT) (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>), one studied intradermal immunotherapy (<a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>), and one studied oral immunotherapy (<a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>). </p> <p>Eight trials compared the intervention with a placebo (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), and four compared the intervention with a standard treatment (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). The duration of treatment was less than a year in one trial, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, and at least a year in <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>, and <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>. </p> </section> <section id="CD008774-sec-0063"> <h5 class="title">Outcomes</h5> <p>With regard to our prespecified primary outcomes, two studies reported 'Participant‐ or parent‐reported global assessment of disease severity at the end of treatment' (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), six studies reported 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures' (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), and seven studies reported 'Adverse events' (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> <p>With regard to our prespecified secondary outcomes, seven studies reported 'Investigator‐ or physician‐rated global assessment of disease severity at the end of treatment' (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>), two studies reported 'Parent‐ or participant‐rated eczema severity assessed using a published scale' in the form of SCORing Atopic Dermatitis (SCORAD) part C (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>), six studies reported 'Investigator‐ or physician‐rated eczema severity assessed using a published scale' (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), eight studies reported 'Use of other medication for treatment of eczema during the intervention period' (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>), and one study reported 'Validated eczema‐related quality of life scores' (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>). </p> <p>Three studies measured other outcomes: one measured total serum immunoglobulin E (IgE) levels, specific IgE levels, and skin prick test results (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>); another measured specific IgE levels and other serum inflammatory parameters associated with either allergic inflammation or its suppression, including eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL‐2R), interferon gamma (IFN‐gamma), or interleukins 4, 5, and 10 (<a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>); and a third measured specific serum IgG4 levels (<a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). </p> <p>Only two of the five publications that reported outcomes from the <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a> study contributed data to the review, because the other three publications did not report atopic eczema outcomes. </p> </section> </section> <section id="CD008774-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We rejected the other 64 titles for the following reasons: not a randomised controlled trial (RCT) (13), not SIT (five), not atopic eczema (AE) (12), review articles (28), and no appropriate control (six). The reason we included these articles for the full text review stage is that from the title or abstract we could not exclude the possibility that they were RCTs of adults or children with AE and allergic sensitisation, but after assessment of the full text, we excluded them. </p> <section id="CD008774-sec-0065"> <h5 class="title">Studies awaiting classification</h5> <p>There were no studies awaiting classification.</p> </section> <section id="CD008774-sec-0066"> <h5 class="title">Ongoing studies</h5> <p>There was one ongoing trial with no outcome data available at the time of review (see the '<a href="./references#CD008774-sec-0114" title="">Characteristics of ongoing studies</a>' table). The contacts for the trial <a href="./references#CD008774-bbs2-0077" title="NCT00310492 . Multicenter, randomized, double‐blind, placebo‐controlled parallel group study to demonstrate the efficacy of a 12‐month subcutaneous specific immunotherapy with ALK‐depot SQ milbenmischung in patients with atopic dermatitis and proven IgE‐mediated sensitization to house dust mites. clinicaltrials.gov/show/NCT00310492 (accessed 18 Nov 2014). ">NCT00310492</a> did not respond to our request for further information. </p> </section> </section> </section> <section id="CD008774-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>Full details are shown in the '<a href="./references#CD008774-sec-0112" title="">Characteristics of included studies</a>' tables. Please see the 'Risk of bias' summary (review authors' judgements about each 'Risk of bias' item for each included study, <a href="#CD008774-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008774-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD008774-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD008774-sec-0068"> <h4 class="title">Random sequence generation</h4> <p>There was a low risk of bias related to generation of randomisation sequence concealment in six studies, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>, <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>, and unclear risk in the following six studies: <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, and <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>. </p> </section> <section id="CD008774-sec-0069"> <h4 class="title">Allocation</h4> <p>There was a low risk of bias related to allocation concealment in three studies (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), high risk in one study (<a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>), and unclear risk in eight studies due to insufficient details provided (<a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). </p> </section> <section id="CD008774-sec-0070"> <h4 class="title">Blinding</h4> <p>There was a low risk of bias related to blinding of participants and personnel in two studies (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), which were either double blinded or triple blinded; high risk in two studies (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), which were open label; and unclear risk in eight studies due to insufficient details provided (<a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> <p>There was a low risk of bias related to blinding of outcome assessors in three studies (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>); high risk in two studies (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), which were open label; and unclear risk in seven studies (<a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>), four of which were unclear regarding whether they included outcome assessors in the double blinding (<a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> </section> <section id="CD008774-sec-0071"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of bias related to incomplete outcome data in four studies, <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>, and <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>, where loss to follow‐up rates were low, and high risk in eight studies where loss to follow up rates were high (up to 51%) or postrandomisation exclusions were noted: <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, and <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>. </p> </section> <section id="CD008774-sec-0072"> <h4 class="title">Selective reporting</h4> <p>There was a low risk of bias related to selective reporting in three studies where the specified outcomes in the methodology were reported in the results, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>, and unclear risk in nine studies: <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, and <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>. </p> </section> <section id="CD008774-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <p>There was low risk of bias related to other sources in nine studies (<a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), high risk in two studies where the manufacturer funded the study either partly or wholly and the authors were affiliated with the manufacturer (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>), and unclear risk in one study where it was unclear whether the authors were affiliated with the manufacturer (<a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>). </p> </section> </section> <section id="CD008774-sec-0074"> <h3 class="title" id="CD008774-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD008774-tbl-0001"><b>Summary of findings for the main comparison</b> Specific allergen immunotherapy versus no immunotherapy</a> </p> <p>See <a href="./full#CD008774-tbl-0001">summary of findings Table for the main comparison</a> for the main comparison 'specific allergen immunotherapy versus no immunotherapy'. </p> <section id="CD008774-sec-0075"> <h4 class="title">Primary outcomes</h4> <section id="CD008774-sec-0076"> <h5 class="title">1. Participant‐ or parent‐reported global assessment of disease severity at the end of treatment </h5> <p>One study, <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>, measured this outcome as whether the eczema was improved, there was no change, or it was worse as rated by the participants or parents. These data were available for 20 participants at the end of the treatment (nine active, 11 placebo), with improvement in 7/9 (78%) of the immunotherapy group and 3/11 (27%) in the placebo group (risk ratio (RR) 2.85, 95% confidence interval (CI) 1.02 to 7.96). Another study, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, measured this outcome as whether the eczema was better, the same, or worse as rated by parents. These data were available for 24 participants, with improvement in 8/13 (62%) of those in the active treatment group and 9/11 (81%) in the placebo group (RR 0.75, 95% CI 0.45 to 1.26)<i>.</i> We did not perform meta‐analysis because of high heterogeneity between the two studies (I² = 83%). The high loss to follow‐up rate and as‐treated analysis in the study by <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a> may have contributed to the significant heterogeneity. The quality of the evidence was low. </p> </section> <section id="CD008774-sec-0077"> <h5 class="title">2. Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures</h5> <p>We used original data shared by the authors of two studies, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a> and <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, to calculate SCORing Atopic Dermatitis (SCORAD) part C scores at the end of treatment, and the components of SCORAD part C, which are itch measured by Visual Analogue Scales (VAS) and sleep disturbance measured by VAS, each on a scale from 0 to 10. Meta‐analysis, with a total of 184 participants, showed no significant difference in SCORAD part C (mean difference (MD) ‐0.74, 95% CI ‐1.98 to 0.50; I² = 0%; <a href="./references#CD008774-fig-0003" title="">Analysis 1.1</a>) or severity of sleep disturbance (MD ‐0.49, 95% CI ‐1.03 to 0.06; I² = 0%; <a href="./references#CD008774-fig-0003" title="">Analysis 1.1</a>). </p> <p>The authors of <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a> provided original data that showed subjective symptom scores at the end of the treatment on a scale of 0 to 100, where higher scores meant more symptoms, and a component of the symptom score, which measured itching severity on a scale of 0 to 10, where higher scores also mean more symptoms. These data were available for 60 participants at the end of the treatment (31 active, 29 placebo), with a mean overall severity score of 37.3 (95% CI 32.4 to 42.1) in the immunotherapy group and 80.8 (95% CI 75.8 to 85.7) in the control group (P &lt; 0.001) and a mean itch severity score of 3.2 (95% CI 2.3 to 4.0) in the immunotherapy group and 7.5 (95% CI 6.9 to 8.0) in the control group (P &lt; 0.001). The difference between groups in change in itch severity score from baseline was also statistically significant (MD ‐4.20, 95% CI ‐3.69 to ‐4.71). </p> <p>For itch severity, we did not meta‐analyse data from these three studies because of extreme heterogeneity (I² = 98%), which was attributable to the open label study of <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>. When we excluded this study from meta‐analysis, combined data from <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a> and <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a> showed no significant difference in SCORAD part C itch severity (MD ‐0.24, 95% CI ‐1.00 to 0.52; I² = 0%). </p> <p>One study, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, reported symptoms in the form of itch score presented graphically that showed no significant difference between the active and placebo groups. One study, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, reported a mean itch score of 2.2 (or 33% reduction from baseline) after immunotherapy compared with 2.6 (or 19% reduction from baseline) in the control group. The authors did not comment on whether this difference was statistically significant and did not respond to our request for further data. </p> <p>Other studies reported insufficient data, such as <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, or did not measure this outcome, such as <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>, and <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>. </p> </section> <section id="CD008774-sec-0078"> <h5 class="title">3. Adverse events</h5> <p>Seven studies reported local or systemic reactions to treatment (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> <p>In addition to individual studies, meta‐analysis, with a total of 484 participants, showed no statistically significant increase in risk of local reactions (RR 1.27, 95% CI 0.89 to 1.81; I² = 25%; <a href="./references#CD008774-fig-0004" title="">Analysis 1.2</a>). Data from seven of the 12 studies contributed to this effect estimate (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> <p>In addition to individual studies, meta‐analysis with a total of 492 participants showed no statistically significant increase in risk of systemic reactions (RR 0.78, 95% CI 0.41 to 1.49; I² = 0%; <a href="./references#CD008774-fig-0004" title="">Analysis 1.2</a>), with 18 events observed in the immunotherapy group and 15 in the control group. Data from four of 12 studies contributed to this effect estimate (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). However, there were no systemic reactions reported in three studies (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). </p> <p>One study, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, with 48 participants, measured other adverse reactions and showed no statistically significant increase in risk of tiredness (RR 5.08, 95% CI 0.66 to 39.02; <a href="./references#CD008774-fig-0004" title="">Analysis 1.2</a>) or headache (RR 2.56, 95% CI 0.11 to 59.75; <a href="./references#CD008774-fig-0004" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD008774-sec-0079"> <h4 class="title">Secondary outcomes</h4> <section id="CD008774-sec-0080"> <h5 class="title">1. Investigator‐ or physician‐rated global assessment of disease severity at the end of treatment </h5> <p>Six studies reported investigator‐ or physician‐rated global assessment of disease severity (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>; <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>). Meta‐analysis, with 262 participants, showed significant improvement in disease severity (RR 1.48, 95% CI 1.16 to 1.88; I² = 19%; <a href="./references#CD008774-fig-0005" title="">Analysis 1.3</a>). </p> <p>One study, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, with 24 participants, reported improvement in 70% of all of the participants that used an investigator‐rated index of disease severity at a threshold of 50% improvement. This was significant between the treatment and the placebo group (P &lt; 0.003), but there were no separate data for the treatment and placebo group, so we could not include them in a meta‐analysis. </p> <p>Other studies did not measure this outcome (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>). </p> </section> <section id="CD008774-sec-0081"> <h5 class="title">2. Parent‐ or participant‐rated eczema severity assessed using a published scale</h5> <p>None of the studies reported participant‐ or parent‐rated eczema severity using a published scale, except for two studies that we have mentioned above, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a> and <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, which recorded SCORAD part C, which we included in this systematic review as a parent‐ or participant‐rated specific eczema symptom (MD ‐0.74, 95% CI ‐1.98 to 0.50; I² = 0%; <a href="./references#CD008774-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD008774-sec-0082"> <h5 class="title">Participant‐ or parent‐rated eczema severity assessed using a non‐published scale</h5> <p>Although this was not a prespecified outcome, we felt it important to include. Four studies measured participant‐ or parent‐rated eczema severity assessed using non‐published Visual Analogue Scales (VAS) on a scale of 0 to 10 (0 = no symptoms, 10 = maximal symptoms). Meta‐analysis of two studies (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>), with a total of 158 participants, showed statistically significant lower end‐of‐treatment VAS scores (MD ‐1.12, 95% CI ‐1.92 to ‐0.32; I² = 0%; <a href="./references#CD008774-fig-0006" title="">Analysis 1.4</a>). We used original data shared by the authors of one study, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, to conduct this analysis. </p> <p>The other two studies only provided original data listed as illustrative text: <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a> reported a VAS that measured overall eczema symptoms with 10.7% improvement in the treatment group and 13.1% worsening in the placebo group (P = 0.07), but the study did not report absolute values. <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a> reported a VAS that measured participant general well‐being with a significant improvement in the treatment group (P = 0.008) but not in the control group, but again, did not report absolute values. Authors of the latter two studies did not respond to our requests for original data for inclusion in a meta‐analysis. </p> </section> <section id="CD008774-sec-0083"> <h5 class="title">3. Investigator‐ or physician‐rated eczema severity assessed using a published scale</h5> <p>Six studies reported 'Investigator‐ or physician‐rated eczema severity assessed using a published scale' in the form of SCORAD (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). Authors of two studies supplied original data for end‐of‐treatment SCORAD (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). Meta‐analysis of three trials (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>), with 244 participants, showed significant improvement in end of treatment SCORAD (MD ‐5.79, 95% CI ‐7.92 to ‐3.66; I² = 0%; <a href="./references#CD008774-fig-0007" title="">Analysis 1.5</a>). </p> <p>One study, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, reported reduction ratios in SCORAD and classified scores as cure (greater than 90%), marked effect (60% to 89%), improvement (20% to 59%), and ineffective (less than 19%). The total efficacy (defined as percentage of participants with change in SCORAD ≥ 60%) was significantly greater in the specific allergen immunotherapy (SIT) group (77.78%) than in the control group (53.85%) (P &lt; 0.05) and was included as a dichotomous 'Investigator‐ or physician‐rated global assessment of disease severity at the end of treatment' outcome in a meta‐analysis in this review (RR 1.48, 95% CI 1.16 to 1.88; I² = 19%; <a href="./references#CD008774-fig-0005" title="">Analysis 1.3</a>). Another study, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, found a significant change in SCORAD between immunotherapy (‐18.4 ± 6.5) and control (‐6.6 ± 4.1) (P = 0.008). This effect was greater for participants with severe eczema at baseline. A further study, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, suggested greater SCORAD improvement with the SIT than in controls in graphical data (P &lt; 0.001), but no numerical data were available. No data for end of treatment SCORAD scores from these three studies were available for inclusion in a meta‐analysis. </p> <p>One study, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, reported no significant difference in a non‐published scale that measured erythema, lichenification, and surface damage between the immunotherapy and the placebo groups. Another study, <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>, reported no significant difference between treatment groups, using a non‐published scale that measured severity of erythema, vesicles, fissuration, lichenification, and itching. </p> </section> <section id="CD008774-sec-0084"> <h5 class="title">4. Use of other medication for treatment of eczema during the intervention period</h5> <p>One study, <a href="./references#CD008774-bbs2-0011" title="SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ Results of a double‐blind, placebo‐controlled study [Spezifische immuntherapie bei der behandlung von patienten mit atopischer dermatitis ‐ Ergebnisse einer plazebokontrollierten doppelblindstudie]. Allergologie2006;29(5):171‐83. [EMBASE: 2006255579] SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis ‐ results of double blind placebo controlled trial. Journal of the European Academy of Dermatology &amp; Venereology2003;17(Suppl 3):155. SilnyW , Czarnecka‐OperaczM . Specific immunotherapy in the treatment of patients with atopic dermatitis‐‐results of double blind placebo controlled study. Polski Merkuriusz Lekarski2006;21(126):558‐65. [MEDLINE: 17405298] SilnyW , Czarnecka‐OperaczM , SilnyP . Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiadomości Lekarskie2005;58(5‐6):287‐94. [MEDLINE: 16238119] SilnyW , Czarnecka‐OperaczM , SilnyP . Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiadomości Lekarskie2005;58(1‐2):47‐55. [MEDLINE: 15991553] ">Silny 2006</a>, with 20 participants, reported no statistically significant difference between the treatment groups in the use of topical steroids for mild to moderate flares of AE (RR 1.33, 95% CI 0.74 to 2.41; <a href="./references#CD008774-fig-0008" title="">Analysis 1.6</a>). Another study, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, reported no significant difference in the use of topical steroids between the treatment groups. (There were no numerical data for meta‐analysis.) One study, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, reported a significant reduction in the use of topical steroids and tacrolimus during one year of immunotherapy (P = 0.02), but there was no such reduction in the control group. </p> <p>Two studies reported the use of systemic steroids for AE. One study, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, with 26 participants, required the use of systemic steroids in 8/16 participants (50%) in the immunotherapy group and 4/10 participants (40%) in the placebo group (P = 0.70). Another study, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, with 60 participants, reported a significant increase in systemic steroid use in 12/29 participants (41%) in the control group compared with 4/31 participants (13%) in the immunotherapy group (P = 0.02). We did not perform meta‐analysis because of the high heterogeneity (I² = 76%). The reason for high heterogeneity between these two studies was unclear. </p> <p>Another study, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, with 168 participants, reported a non‐significant 32% difference in the median AUC (area under the curve) of medication score, a culmination of topical medication and overall consumption of systemic medication (19,330 in the immunotherapy group and 28,420 in the placebo group; P = 0.08). These data were not in a format suitable for incorporation into a meta‐analysis. </p> <p>One study, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, reported a significant decrease in the use of rescue medications (oral hydroxyzine and topical steroids, respectively) in the immunotherapy group. There were 171 occasions where rescue medications were used in the immunotherapy group compared with 346 occasions in the placebo group (P = 0.03). The rescue medications were used on 93 days in the immunotherapy group and 158 days in the placebo groups (P = 0.01). </p> <p>One study, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, reported significantly less use of rescue medications (not defined) in the treatment group compared with the control group, but no details were provided. </p> <p>Another study, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, reported an average daily drug score (one point for symptomatic use of levocetirizine hydrochloride tablet, mometasone furoate cream, or mupirocin ointment each day; and six points for every six‐day course of clarithromycin for superinfection). Average daily drug score was lower in the treatment group (mean 0.5, standard deviation (SD) 0.4) than in the control group (mean 1.3, SD 0.7) (P &lt; 0.01). </p> <p>Other studies did not report this outcome (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0002" title="GalliE , ChiniL , NardiS , BenincoriN , PaneiP , FraioliG , et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergologia et immunopathologia1994;22(1):18‐22. [MEDLINE: 8030579] ">Galli 1994</a>; <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>). None of the studies reported the use of oral antihistamines or calcineurin inhibitors as separate outcomes. </p> </section> <section id="CD008774-sec-0085"> <h5 class="title">5. Validated eczema‐related quality of life scores</h5> <p>One study, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, reported a validated eczema‐related quality of life score, the Dermatology Life Quality Index (DLQI), at the end of treatment. We used original data kindly provided by the trial authors to calculate DLQI at the end of treatment, which showed no difference between the treatment groups ‐ a median of 3 (interquartile range (IQR) 1.0 to 8.0) for immunotherapy and a median of 3.5 (IQR 1.0 to 10.5) for placebo (P = 0.525). </p> </section> </section> <section id="CD008774-sec-0086"> <h4 class="title">Subgroup analyses</h4> <p>We undertook 16 planned subgroup analyses where data were available. We did not undertake further sensitivity analyses because of the small number of trials that contributed data to the analyses. </p> <p> <ol id="CD008774-list-0007"> <li> <p>Immunotherapy type: sublingual and subcutaneous.</p> </li> <li> <p>Allergen type: seasonal inhalant, perennial inhalant, food, and microbial.</p> </li> <li> <p>Age of participants: up to four years, five to 11, 12 to 17, and 18 or over.</p> </li> <li> <p>Immunotherapy regimens to be subdivided empirically into low, intermediate, and high dose therapy according to content of major allergen per dose (e.g. <i>Phleum</i> p5 for grass, Bet v1 for birch pollen, Fel d1 for cat, etc.): </p> <ol id="CD008774-list-0008"> <li> <p>for subcutaneous immunotherapy, content of major allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11 mcg per four‐ to six‐weekly maintenance injection doses; and </p> </li> <li> <p>for sublingual immunotherapy, content of major allergen 1 mcg to 5 mcg, 6 mcg to 10 mcg, and greater than 11 mcg per daily maintenance sublingual dose (or equivalent if taken less frequently). </p> </li> </ol> </li> <li> <p>Severity of AE at randomisation: mild (SCORAD mean objective score of 0 to 15), moderate (SCORAD mean objective score of 16 to 40), and severe (SCORAD mean objective score of greater than 40). </p> </li> </ol> </p> <p>First, we analysed our primary outcome measure 'Participant‐ or parent‐reported global assessment of disease severity at the end of treatment'. Two studies reported dichotomous outcomes that we did not combine in meta‐analyses because of significant heterogeneity (I² = 83%) (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>; <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>). We did not perform subgroup analyses because both studies fell under the same subgroup categories (subcutaneous route, perennial allergen, and both children and adults). One study, <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>, showed significant improvement in 7/9 participants (78%) in the immunotherapy group compared with 3/11 participants (27%) in the placebo group (P = 0.04). Another study, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, showed significant improvement in 8/13 participants (62%) in the active group compared with 9/11 (81%) in the placebo group (P = 0.38). </p> <p>Next, we analysed our primary outcome measure 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures' in nine subgroup analyses. We found no evidence that this outcome differed according to the following. </p> <p> <ul id="CD008774-list-0009"> <li> <p>Route of immunotherapy: SCORAD part C (subcutaneous: MD ‐0.62, 95% CI ‐2.18 to 0.93) (sublingual: MD ‐0.94, 95% CI ‐3.00 to 1.13) (test for subgroup differences: I² = 0%; <a href="./references#CD008774-fig-0009" title="">Analysis 2.1</a>). With regard to itch, meta‐analysis was not possible due to extreme heterogeneity (I² = 99%) attributable to the study of <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>. Without this study in the analysis, the test for subgroup difference between sublingual and subcutaneous immunotherapies and their controls was not significant (I² = 0%) for sleep disturbance (subcutaneous: MD ‐0.42, 95% CI ‐1.24 to 0.40) (sublingual: MD ‐0.54, 95% CI ‐1.27 to 0.19) (test for subgroup differences: I² = 0%; <a href="./references#CD008774-fig-0010" title="">Analysis 2.2</a>). </p> </li> <li> <p>Allergen type: SCORAD part C (seasonal inhalant: MD not estimable) (perennial inhalant: MD ‐0.74, 95% CI ‐1.98 to 0.50; <a href="./references#CD008774-fig-0011" title="">Analysis 2.3</a>) (food: MD not estimable) (microbial: MD not estimable). With regard to itch, meta‐analysis was not possible due to extreme heterogeneity (I² = 99%) attributable to the study of <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>. Without this study in the analysis, the test for subgroup differences for seasonal inhalant and perennial inhalant immunotherapies was not significant (I² = 0%) for sleep disturbance (seasonal inhalant: MD not estimable) (perennial inhalant: MD ‐0.49, 95% CI ‐1.03 to 0.06; <a href="./references#CD008774-fig-0012" title="">Analysis 2.4</a>) (food: MD not estimable) (microbial: MD not estimable). </p> </li> <li> <p>Participant age: SCORAD part C (up to four years: MD not estimable) (five to 11 years of age: MD not estimable) (12 to 17 years of age: MD not estimable) (18 years of age or over: (MD ‐0.62, 95% CI ‐2.18 to 0.93; <a href="./references#CD008774-fig-0013" title="">Analysis 2.5</a>); itch (up to four years of age: MD not estimable) (five to 11 years of age: MD not estimable) (12 to 17 years of age: MD not estimable) (18 years of age or over: MD ‐0.20, 95% CI ‐1.05 to 0.64; <a href="./references#CD008774-fig-0014" title="">Analysis 2.6</a>); or sleep disturbance (up to four years of age: MD not estimable) (five to 11 years of age: MD not estimable) (12 to 17 years of age: MD not estimable) (18 years of age or over: MD ‐0.42, 95% CI ‐1.24 to 0.40; <a href="./references#CD008774-fig-0015" title="">Analysis 2.7</a>). </p> </li> <li> <p>Severity at randomisation using original data from one study for the outcomes itch and sleep disturbance (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>). In the moderate severity subgroup, data were available for 37 participants (23 in the immunotherapy group and 14 in the placebo group): itch did not differ significantly between groups ‐ with a median of 1.7 (IQR 0.3 to 3.5) for immunotherapy and 1.7 (IQR 0.5 to 3.7) for placebo (P = 0.96) ‐ nor did sleep disturbance ‐ with a median of 0.3 (IQR 0.1 to 2.8) for immunotherapy and 0.5 (IQR 0.3 to 1.5) for placebo (P = 0.53). In the severe subgroup, data were available for 109 participants (75 in the active group and 34 in the placebo group): itch did not differ significantly between groups ‐ with a median of 2.0 (IQR 0.7 to 4.1) for immunotherapy and 2.9 (IQR 1.3 to 5.4) for placebo (P = 0.22) ‐ nor did sleep disturbance ‐ with a median of 1.1 (IQR 0.4 to 3.3) for immunotherapy and 1.9 (IQR 0.6 to 5.1) for placebo (P = 0.14). During treatment, we also calculated the change in itch in the moderate (MD 1.01, 95% CI ‐1.31 to 3.33) and severe subgroups (MD 0.10, 95% CI ‐1.38 to 1.58; <a href="./references#CD008774-fig-0016" title="">Analysis 2.8</a>) and sleep disturbance in the moderate (MD 0.38, 95% CI ‐1.32 to 2.09) and severe subgroups (MD ‐0.31, 95% CI ‐1.66 to 1.04; <a href="./references#CD008774-fig-0017" title="">Analysis 2.9</a>). We found no significant difference between the immunotherapy and control groups. </p> </li> </ul> </p> <p>Last, we analysed our primary outcome 'Adverse events' in six subgroup analyses. We found evidence that this outcome differed significantly according to the following: </p> <p> <ul id="CD008774-list-0010"> <li> <p>route of immunotherapy: local reactions were greater in the immunotherapy group than the control group by the sublingual (RR 9.76, 95% CI 1.28 to 74.26) but not the subcutaneous route (RR 1.18, 95% CI 0.90 to 1.55) (test for subgroup differences: I² = 76%; <a href="./references#CD008774-fig-0018" title="">Analysis 2.10</a>). </p> </li> </ul> </p> <p>We found no evidence that this outcome differed between the immunotherapy or control groups according to the following: </p> <p> <ul id="CD008774-list-0011"> <li> <p>route of immunotherapy: systemic reactions (subcutaneous: RR 0.82, 95% CI 0.34 to 2.00) (sublingual: RR 0.74, 95% CI 0.29 to 1.89) (test for subgroup differences: I² = 0%; <a href="./references#CD008774-fig-0019" title="">Analysis 2.11</a>); </p> </li> <li> <p>allergen type: local reactions (seasonal inhalant: RR not estimable) (perennial inhalant: RR 1.31, 95% CI 0.81 to 2.13; <a href="./references#CD008774-fig-0020" title="">Analysis 2.12</a>) (food: RR not estimable) (microbial: RR not estimable); systemic reactions (seasonal inhalant: RR not estimable) (perennial inhalant: RR 0.78, 95% CI 0.41 to 1.49; <a href="./references#CD008774-fig-0021" title="">Analysis 2.13</a>) (food: RR not estimable) (microbial: RR not estimable); and </p> </li> <li> <p>participant age: local reactions (up to four years: RR not estimable) (five to 11: RR not estimable) (12 to 17: RR not estimable) (18 years or over: RR 1.37, 95% CI 0.44 to 4.23; <a href="./references#CD008774-fig-0022" title="">Analysis 2.14</a>); systemic reactions (up to four years: RR not estimable) (five to 11: RR not estimable) (12 to 17: RR not estimable) (18 years or over: RR 0.74, 95% CI 0.38 to 1.47; <a href="./references#CD008774-fig-0023" title="">Analysis 2.15</a>). </p> </li> </ul> </p> <p>There were no data available for other subgroup analyses of our primary outcomes.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008774-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008774-sec-0087">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008774-sec-0129">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008774-sec-0087"></div> <section id="CD008774-sec-0088"> <h3 class="title" id="CD008774-sec-0088">Summary of main results</h3> <p>We identified 12 randomised controlled clinical trials of specific allergen immunotherapy (SIT) for the treatment of atopic eczema (AE), which included 733 participants with eczema and allergic sensitisation to an inhalant allergen. The studies were of children and adult participants allergic to house dust mite, grass pollen, and other inhalant allergens; and immunotherapy via subcutaneous, sublingual, oral, and intradermal routes. We judged nine studies to have a high risk of bias due to high rates of loss to follow up or postrandomisation exclusions, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>, <a href="./references#CD008774-bbs2-0004" title="KaufmanHS , RothHL . Hyposensitization with alum precipitated extracts in atopic dermatitis: A placebo‐controlled study. Annals of Allergy1974;32(6):321‐30. [MEDLINE: 4597822] ">Kaufman 1974</a>, <a href="./references#CD008774-bbs2-0005" title="LeroyB , LachapelleJM , JacqueminMG , Saint‐RemyJM . Immunotherapy of atopic dermatitis by injections of antigen‐antibody complexes. Dermatology1993;186(4):276‐7. [MEDLINE: 8513198] LeroyBP , BodenG , JacqueminMG , LachapelleJM , Saint‐RemyJM . Allergen‐antibody complexes in the treatment of atopic dermatitis: preliminary results of a double‐blind placebo‐controlled study. Acta Dermato‐Venereologica. Supplementum1992;176:129‐31. [MEDLINE: 1476025] LeroyBP , BodenG , LachapelleJM , JacqueminMG , Saint‐RemyJM . A novel therapy for atopic dermatitis with allergen‐antibody complexes: A double‐blind, placebo‐controlled study. Journal of the American Academy of Dermatology1993;28(2 Pt 1):232‐9. [MEDLINE: 8432921] ">Leroy 1993</a>, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, <a href="./references#CD008774-bbs2-0008" title="PajnoG , CaminitiL , VitaD , BarberioG , SalzanoG , LombardoF , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, double‐blind, placebo‐controlled study. Journal of Allergy &amp; Clinical Immunology2007;120(1):164‐70. [MEDLINE: 17543376] PajnoG , VitaD , CaminitiL , ArrigoT , LombardoF , BarberioG . House dust mite sublingual immunotherapy (SLIT) for atopic dermatitis (AD) a randomized controlled trial. Journal of Allergy &amp; Clinical Immunology2006;117(2 Suppl 1):S233. PajnoGB , CaminitiL , VitaD , ProfazioC . Sublingual House Dust Mite (hdm) Immunotherapy, In Children With Extrinsic Allergic Form Of Atopic Dermatitis. A Randomized Controlled Trial On Prevention Of Appearance Of Asthma Or Rhinitis. 2010 American Academy of Allergy, Asthma and Immunology, AAAAI Annual Meeting New Orleans, LA United States. 26 February ‐ 2 March 2010. Journal of Allergy &amp; Clinical Immunology2010;125(2 Suppl 1):AB236. [EMBASE: 70156028] PassalacquaG , CompalatiE , CanonicaGW . Sublingual Immunotherapy: Clinical Indications in the WAO‐SLIT Position Paper. World Allergy Organization Journal2010;3(7):216‐9. [MEDLINE: 23282652] PassalacquaG , PajnoG . Long‐term prevention of asthma/rhinitis in children with atopic dermatitis 4 years after stopping sublingual immunotherapy. Allergy: European Journal of Allergy &amp; Clinical Immunology2012;67(Suppl 96):89. [EMBASE: 71109979] ">Pajno 2007</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, or non‐blinded outcome assessment, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>. </p> <p>For our prespecified primary outcomes 'Participant‐ or parent‐reported global assessment of disease severity at the end of treatment' (two studies, 44 participants, low quality evidence) and 'Participant‐ or parent‐reported specific symptoms of eczema, by subjective measures' (six studies, 339 participants, very low quality evidence), SIT is not an effective treatment for AE (<a href="./full#CD008774-tbl-0001">summary of findings Table for the main comparison</a>). However, the results for our secondary outcomes 'Investigator‐ or physician‐rated global assessment of disease activity at the end of treatment' (seven studies, 286 participants) and 'Investigator‐ or physician‐rated eczema severity assessed using a published scale (e.g. SCORing Atopic Dermatitis (SCORAD))' (six studies, 435 participants) indicated SIT was effective, although the quality of the evidence was low and very low for these two outcomes, respectively. Our other secondary outcomes 'Parent‐ or participant‐rated eczema severity assessed using a published scale' (two studies, 184 participants) and 'Validated eczema‐related quality of life scores' (one study, 168 participants) showed no difference with SIT. </p> <p>For our primary outcome 'Adverse events', SIT was not associated with increased risk of local (seven studies, 484 participants) or systemic (seven studies, 492 participants, moderate evidence) adverse reactions. Also, SIT was not associated with an increased need for topical (one study, 20 participants) or systemic (two studies, 86 participants) corticosteroid use during the studies. </p> <p>Three studies had more positive findings than the others. One, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, reported a marked improvement in participant‐ or parent‐reported symptoms and smaller but statistically significant improvements in investigator‐ or physician‐reported global eczema severity and total SCORAD (a 5.8‐point greater improvement) compared with untreated participants. Another, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, reported a significantly greater investigator‐ or physician‐rated global disease severity, defined as change in SCORAD ≥ 60% in SIT (77.78%) compared with the control (53.85%) (P &lt; 0.05). A further study, <a href="./references#CD008774-bbs2-0006" title="Luna‐PechJA , Newton‐SanchezOA , Torres‐MendozaBM , Garcia‐CobasCY . Efficacy of sublingual immunotherapy in the severity of atopic dermatitis in children with allergic sensitization to dermatophagoides pteronyssinus. 2013 Annual Meeting of the American College of Allergy, Asthma and Immunology Baltimore, MD United States. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A8. [EMBASE: 71306835] ">Luna‐Pech 2013</a>, reported a significant change in investigator‐ or physician‐rated global disease severity through assessment of SCORAD in SIT (mean ‐18.4, SD 6.5) compared with the control (mean ‐6.6, SD 4.1) (P = 0.008), with a greater effect in those with severe eczema at baseline. No original data were available for inclusion in meta‐analyses. </p> <p>Subgroup analyses identified a low confidence of effect that sublingual immunotherapy was associated with more local adverse reactions compared with subcutaneous immunotherapy. Other subgroup analyses did not identify a type of allergen, a participant age, or a severity of AE at randomisation with a different efficacy or safety profile, although these analyses were generally inconclusive due to the limited data available. </p> </section> <section id="CD008774-sec-0089"> <h3 class="title" id="CD008774-sec-0089">Overall completeness and applicability of evidence</h3> <p>Overall, we found low quality of evidence that specific allergen immunotherapy is effective in the treatment of atopic eczema. The varied disease severity scales and symptom scores used across the trials generally limited the meta‐analyses. In those with comparable data, some outcomes were significant. Wide confidence intervals for many outcome measures reflected relatively small studies and varied methodologies. Several outcomes were based on analysis from a single trial, <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>, with a large number of participants but high loss to follow up. Three trials, <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>, <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>, <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>, had more positive findings than the others and showed a clear beneficial effect on participant‐ or parent‐reported eczema symptoms and investigator‐ or physician‐reported global eczema severity in the form of SCORAD. It is not clear why the findings of these trials differed, but there was a risk of detection bias due to lack of blinding of participants or investigators in at least two trials (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). We found that adverse reaction rates were not significantly increased with immunotherapy in the included studies, but other evidence suggests that SIT carries a significantly increased risk of severe allergic reactions (<a href="./references#CD008774-bbs2-0087" title="CalderonMA , AlvesB , JacobsonM , HurwitzB , SheikhA , DurhamS . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001936.pub2] ">Calderon 2007</a>). While this might suggest that the allergic sensitisation present in the trial participants is of little clinical relevance or that the allergen extracts used were of low potency, it may equally reflect the small number of trials and participants that contributed to the adverse events analyses. </p> </section> <section id="CD008774-sec-0090"> <h3 class="title" id="CD008774-sec-0090">Quality of the evidence</h3> <p>Our overall judgement of the quality of the body of evidence that contributed to the results of the review, using the Grading of Recommendations Assessment, Development and Education (GRADE) approach (<a href="./references#CD008774-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org., Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), was low. The reasons we downgraded were relatively few trials and participants, lack of blinding in at least two trials, wide confidence intervals, moderate risk of bias with high loss to follow up as the main concern, and significant heterogeneity between the estimate of treatment effects for a primary outcome. </p> </section> <section id="CD008774-sec-0091"> <h3 class="title" id="CD008774-sec-0091">Potential biases in the review process</h3> <p>The strengths of this review were the adherence to our published protocol and the repeated efforts to acquire original data from study authors in order to maximise opportunities for meta‐analysis and clarify methodological uncertainties. The limited number of included studies did not allow formal assessment for publication bias. We analysed different outcome measures as separate analyses, which limited the opportunities to pool data from different studies that used different outcome assessment tools. </p> </section> <section id="CD008774-sec-0092"> <h3 class="title" id="CD008774-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>Three other systematic reviews of SIT for the treatment of AE have been undertaken. In one review (<a href="./references#CD008774-bbs2-0082" title="BaeJM , ChoiYY , ParkCO , ChungKY , LeeKH . Efficacy of allergen‐specific immunotherapy for atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials. Journal of Allergy &amp; Clinical Immunology2013;132(1):110‐7. [MEDLINE: 23647790] ">Bae 2013</a>), the authors identified eight of the 12 trials included in this review but analysed the data in a different way, by pooling heterogeneous outcomes 'measured by any scoring systems', which may not be appropriate (<a href="./references#CD008774-bbs2-0109" title="TamH , CalderonMA , BoyleRJ . Efficacy of allergen‐specific immunotherapy for patients with atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2013;132(4):1012‐3. [MEDLINE: 23993878] ">Tam 2013</a>). In contrast to our review, they found moderate evidence that SIT may be an effective treatment for AE both in all participants studied (odds ratio (OR) for improved eczema 5.35, 95% confidence interval (CI) 1.61 to 17.77) and in subgroup analyses of participants with severe eczema at randomisation (OR 3.13, 95% CI 1.31 to 7.47) and studies that used subcutaneous immunotherapy (OR 4.27, 95% CI 1.36 to 13.39). The different outcomes in their review are likely due to the unconventional approaches for extracting and combining data from the included trials. There was no registered protocol for their review, so we cannot confirm that the inclusion criteria and outcome measures were determined a priori. </p> <p>In a systematic review that used the GRADE recommendations (<a href="./references#CD008774-bbs2-0025" title="GendelmanSR , LangDM . Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Annals of Allergy, Asthma &amp; Immunology2013;111(6):555‐61. [MEDLINE: 24267368] ">Gendelman 2013</a>), the authors identified five of the nine trials included in our review, and an additional two that we excluded (<a href="./references#CD008774-bbs2-0054" title="RingJ . Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. British Journal of Dermatology1982;107(5):597‐602. [MEDLINE: 6751375] ">Ring 1982</a>; <a href="./references#CD008774-bbs2-0069" title="WerfelT , BreuerK , RueffF , PrzybillaB , WormM , GreweM , et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi‐centre, randomized, dose‐response study. Allergy2006;61(2):202‐5. [MEDLINE: 16409197] ">Werfel 2006</a>). The review did not perform meta‐analyses. Similar to our review, they found only weak strength of recommendations for the use of SIT to treat AE. They also reported similar methodological shortcomings, including high losses to follow up. </p> <p>In a similar systematic review on sublingual immunotherapy only that used the GRADE recommendations (<a href="./references#CD008774-bbs2-0027" title="GendelmanS , LangDM . Sublingual Immunotherapy in the Treatment of AtopicDermatitis: a Systematic Review Using the GRADE System. Current Allergy and Asthma Reports2015;15(2):498. ">Gendelman 2015</a>), the authors identified three of the 12 trials included in our review and an additional two that we excluded (<a href="./references#CD008774-bbs2-0017" title="CadarioG , GalluccioAG , PezzaM , AppinoA , MilaniM , PecoraS , et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: A prospective pilot study. Current Medical Research &amp; Opinion2007;23(10):2503‐6. [MEDLINE: 17784996] ">Cadario 2007</a>; <a href="./references#CD008774-bbs2-0037" title="MastrandreaF , SerioG , MinelliM , MinardiA , ScarciaG , CoradduzzaG , et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6‐year follow‐up of 35 consecutive patients. Allergologia et Immunopathologia2000;28(2):54‐62. [MEDLINE: 10804094] ">Mastrandrea 2000</a>). The review did not perform meta‐analyses. Similar to our study, they found only weak strength of recommendations for the use of sublingual immunotherapy to treat AE with a large placebo effect in two studies. They also reported similar methodological shortcomings, which included lack of blinding, lack of control, and lack of randomisation. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008774-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD008774-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD008774-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 1 Participant‐ or parent‐reported specific symptoms of eczema." data-id="CD008774-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 1 Participant‐ or parent‐reported specific symptoms of eczema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 2 Adverse events." data-id="CD008774-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 2 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 3 Investigator‐ or physician‐rated global disease severity." data-id="CD008774-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 3 Investigator‐ or physician‐rated global disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 4 Participant‐ or parent‐rated eczema severity using a non‐published scale." data-id="CD008774-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 4 Participant‐ or parent‐rated eczema severity using a non‐published scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 5 Investigator‐rated eczema severity assessed using a published scale." data-id="CD008774-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 5 Investigator‐rated eczema severity assessed using a published scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Immunotherapy versus control, Outcome 6 Use of other medications for eczema." data-id="CD008774-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Immunotherapy versus control, Outcome 6 Use of other medications for eczema. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 1 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by route of immunotherapy." data-id="CD008774-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 1 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by route of immunotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 2 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by route of immunotherapy." data-id="CD008774-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 2 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by route of immunotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 3 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by allergen type." data-id="CD008774-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 3 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by allergen type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 4 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by allergen type." data-id="CD008774-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 4 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by allergen type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 5 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by participant age." data-id="CD008774-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 5 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by participant age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 6 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by participant age." data-id="CD008774-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 6 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by participant age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 7 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by participant age." data-id="CD008774-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 7 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by participant age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 8 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by severity at randomisation." data-id="CD008774-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 8 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by severity at randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 9 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by severity at randomisation." data-id="CD008774-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 9 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by severity at randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 10 Adverse events: any local reaction by route of immunotherapy." data-id="CD008774-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 10 Adverse events: any local reaction by route of immunotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 11 Adverse events: any systemic reaction by route of immunotherapy." data-id="CD008774-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 11 Adverse events: any systemic reaction by route of immunotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 12 Adverse events: any local reaction by allergen type." data-id="CD008774-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 12 Adverse events: any local reaction by allergen type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 13 Adverse events: any systemic reaction by allergen type." data-id="CD008774-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 13 Adverse events: any systemic reaction by allergen type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 14 Adverse events: any local reaction by participant age." data-id="CD008774-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 14 Adverse events: any local reaction by participant age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008774-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/urn:x-wiley:14651858:media:CD008774:CD008774-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_t/tCD008774-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 15 Adverse events: any systemic reaction by participant age." data-id="CD008774-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Planned subgroup analyses: immunotherapy versus control, Outcome 15 Adverse events: any systemic reaction by participant age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/media/CDSR/CD008774/image_n/nCD008774-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008774-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Specific allergen immunotherapy versus no immunotherapy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Specific immunotherapy compared with no immunotherapy for atopic eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with atopic eczema and inhalant allergen sensitisation </p> <p><b>Settings:</b> specialist allergy centres in the UK (2 trials), Italy (3 trials), USA, Germany, Belgium, Poland, Columbia, and China </p> <p><b>Intervention:</b> specific allergen immunotherapy </p> <p><b>Comparison:</b> no immunotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No immunotherapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Specific allergen immunotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐ or parent‐reported global assessment of disease severity</b> </p> <p>Follow‐up: 6 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<sup>a</sup> <br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in 7/9 participants (78%) in the immunotherapy group and 3/11 participants (27%) in the placebo group (RR 2.85, 95% CI 1.02 to 7.96; P = 0.04 (<a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>)) </p> <p>8/13 participants (62%) in the immunotherapy group and 9/11 participants (81%) in the placebo group (RR 0.75, 95% CI 0.45 to 1.26; P = 0.38 (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a>)) </p> <p>Due to unexplained statistical heterogeneity, we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐ or parent‐reported specific symptoms of eczema</b> </p> <p>Follow‐up: 12 to 18 months</p> <p>SCORAD part C measured as a combination of 2 Visual Analogue Scales (1 for itch, 1 for sleep disturbance), each on a scale from 0, no specific symptoms, to 10, maximum specific symptoms </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD part C score ranged across control groups from <b>3.07 to 5.29</b> </p> <p>The mean SCORAD part C sleep severity score ranged across control groups from <b>0.8 to 2.31</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD part C score in the immunotherapy group was on average <b>0.74 lower (95% CI ‐1.98 to 0.50)</b> </p> <p>The mean SCORAD part C sleep severity score in the immunotherapy group was on average <b>0.49 lower (95% CI ‐1.03 to 0.06)</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339<sup>a</sup> </p> <p>(6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Itch: SCORAD part C itch severity at the end of treatment: MD ‐0.24, 95% CI ‐1.00 to 0.52; I² = 0% for <a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a> and <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a> </p> <p>Itch severity score: MD ‐4.20, 95% CI ‐3.69 to ‐4.71 for <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a> </p> <p>Due to unexplained statistical heterogeneity, we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events ‐ any systemic reaction</b> </p> <p>Follow‐up: 6 to 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.78</b> (0.41 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>492<sup>a</sup> <br/> (7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> <br/> (29 to 106) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>163 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> <br/> (67 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Investigator‐ or physician‐rated global assessment of disease severity</b> </p> <p>Follow‐up: 1 to 3 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low‐risk population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 1.48</b> (1.16 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>286<sup>a</sup> </p> <p>(7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> <p>(0 to 10)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>697 per 1000</b> </p> <p>(546 to 885)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High‐risk population</b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>778 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1151 per 1000</b> </p> <p>(903 to 1462)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐ or physician‐rated eczema severity using a published scale</b> </p> <p>Follow‐up: 12 to 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD score ranged across control groups from <b>26.7 to 32.6</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean SCORAD score in the immunotherapy group was on average <b>5.79 lower (95% CI ‐7.92 to ‐3.66)</b> </p> <p>(<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<sup>a</sup> </p> <p>(6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant or parent‐rated eczema severity using a published scale</b> </p> <p>Follow‐up: 12 to 18 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184<sup>a</sup> <br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD part C used as the specific eczema symptom score (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IQR:</b> interquartile range; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>SCORAD</b>: SCORing Atopic Dermatitis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Assumed risks are based on the total control group risk across all included studies (medium risk population) and the included studies with the lowest (low risk population) and highest (high risk population) control group risks.<br/> <sup>a</sup>The number of total participants did not include those that were lost to follow up. The number of total participants and trials included those that contributed to narrative synthesis.<br/> <sup>b</sup>We downgraded the quality of the evidence by two levels because of unexplained heterogeneity (serious, ‐1) and imprecision (serious, ‐1). There was significant heterogeneity (I² = 83%) between the estimate of dichotomous effects in two studies (<a href="./references#CD008774-bbs2-0003" title="GloverMT , AtheronDJ . A double‐blind controlled trial of hyposensitization to the house dust mite in childhood atopic eczema. British Journal of Dermatology1991;125(Suppl s38):87. GloverMT , AthertonDJ . A double‐blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clinical &amp; Experimental Allergy1992;22(4):440‐6. [MEDLINE: 1611544] ">Glover 1992</a> and <a href="./references#CD008774-bbs2-0012" title="WarnerJO , PriceJF , SoothillJF , HeyEN . Controlled trial of hyposensitisation to dermatophagoides pteronyssinus in children with asthma. Lancet1978;2(8096):912‐5. [MEDLINE: 81927] ">Warner 1978</a>), and data were not pooled. The information size was small.<br/> <sup>c</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐1), imprecision (serious, ‐1), and unexplained heterogeneity (serious, ‐1). Two trials were non‐blinded (<a href="./references#CD008774-bbs2-0001" title="DiRienzoV , CadarioG , GriecoT , GalluccioAG , CaffarelliC , Liotta , et al. Sublingual immunotherapy in mite‐sensitized children with atopic dermatitis: A randomized, open, parallel‐group study. Annals of Allergy, Asthma &amp; Immunology2014;113(6):671‐3. [PUBMED: 25304342] EudraCT2008‐000196‐23 . Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild‐to‐moderate atopic eczema (AE) and sensitization to HDM (SPT positive) ( SLO‐AD‐1 Italy). www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐000196‐23/IT (accessed 1 December 2015). ">Di Rienzo 2014</a>; <a href="./references#CD008774-bbs2-0010" title="Sanchez CaraballoJM , Cardona VillaR . Clinical and Immunological Changes of Immunotherapy in Patients with Atopic Dermatitis: Randomized Controlled Trial. Isrn Allergy Online2012;2012(183983):9 pages. [DOI: 10.5402/2012/183983; MEDLINE: 23724240] ">Sanchez 2012</a>). Moderate proportions of participants were not analysed (losses to follow up). The information size was small. Most subgroups of estimate of treatment effects were not significant, with high heterogeneity displayed by itch (I² = 98%). We did not pool data from all studies because of different symptoms and different scoring systems reported.<br/> <sup>d</sup>We downgraded the quality of the evidence by one level because of imprecision (serious, ‐1). The estimate of treatment effect relied largely on two studies (<a href="./references#CD008774-bbs2-0007" title="NovakN , BieberT , HoffmanM , Folster‐HolstM , HomeyB , WerfelT , et al. Efficacy and safety of subcutaneous allergen‐specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. Journal of Allergy &amp; Clinical Immunology2012;130(4):925‐31. [MEDLINE: 22947344] NovakN , ZuberbierT , SagerA . Efficacy and safety of a depigmented polymerised mite extract in patients suffering from atopic eczema with clinical relevant IgE‐mediated sensitisation against house dust mites. 30th Congress of the European Academy of Allergy and Clinical Immunology Istanbul Turkey. Conference Start: 20110611 Conference End: 20110615. Allergy: European Journal of Allergy and Clinical Immunology2011;66(Suppl s94):103. [EMBASE: 70640604] ">Novak 2012</a>; <a href="./references#CD008774-bbs2-0009" title="NCT01471119 . Sublingual Immunotherapy in Patients With Atopic Dermatitis. clinicaltrials.gov/ct2/show/NCT01471119 (accessed 1 December 2015). QinYE , MaoJR , SangYC , LiWX . Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. International Journal of Dermatology2014;53(5):650‐655. [MEDLINE: 23968339] ">Qin 2014</a>). It is unclear whether the estimate obtained from a small number of adverse reactions to two different dust mite extracts can be generalised. Indeed, data from other populations suggest that specific allergen immunotherapy is generally associated with a small but significant risk of systemic adverse reactions.<br/> <sup>e</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐2) and imprecision (serious, ‐1). The estimate of treatment effect relied on two non‐blinded studies. The information size was small.<br/> <sup>f</sup>We downgraded the quality of the evidence by three levels because of study limitations (serious, ‐2) and imprecision (serious, ‐1). Two studies were non‐blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small.<br/> <sup>g</sup>We downgraded the quality of the evidence by two levels because of study limitations (serious, ‐1) and imprecision (serious, ‐1). One study was non‐blinded. Moderate proportions of participants were not analysed (losses to follow up). The information size was small. We did not include analyses of non‐published scales in this summary table. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Specific allergen immunotherapy versus no immunotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008774-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaphylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A serious, life‐threatening allergic reaction</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fissuration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Formation of tears in the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intradermally</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Into the skin (dermis), below the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lichenification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thickening and hardening of the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Monovalent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 kind of antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perennial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long‐lasting continually</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Photopheresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A form of apheresis and photodynamic therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Under the tongue</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluid‐filled cavities</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/full#CD008774-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008774-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Immunotherapy versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐ or parent‐reported specific symptoms of eczema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 SCORAD part C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.98, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Severity of sleep disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.03, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Any local reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.89, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Any systemic reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.41, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.08 [0.66, 39.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.11, 59.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐ or physician‐rated global disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.16, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participant‐ or parent‐rated eczema severity using a non‐published scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐1.92, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐rated eczema severity assessed using a published scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Total SCORAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.79 [‐7.92, ‐3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Use of other medications for eczema <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Immunotherapy versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008774-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Planned subgroup analyses: immunotherapy versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by route of immunotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Subcutaneous immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Sublingual immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by route of immunotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Subcutaneous immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sublingual immunotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by allergen type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Perennial inhalant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.74 [‐1.98, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by allergen type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Perennial inhalant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐1.03, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Participant‐ or parent‐reported specific symptoms of eczema ‐ SCORAD part C by participant age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 18 years or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by participant age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 18 years or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by participant age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 18 years or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Participant‐ or parent‐reported specific symptoms of eczema ‐ itch severity by severity at randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Moderate (SCORAD mean objective score 16 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Severe (SCORAD mean objective score &gt; 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Participant‐ or parent‐reported specific symptoms of eczema ‐ severity of sleep disturbance by severity at randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Moderate (SCORAD mean objective score 16 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Severe (SCORAD mean objective score &gt; 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events: any local reaction by route of immunotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.90, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.76 [1.28, 74.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events: any systemic reaction by route of immunotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Subcutaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.34, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Sublingual</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.29, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events: any local reaction by allergen type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Perennial inhalant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.81, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events: any systemic reaction by allergen type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Perennial inhalant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.41, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events: any local reaction by participant age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 18 years or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.44, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events: any systemic reaction by participant age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 18 years or over</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.38, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Planned subgroup analyses: immunotherapy versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008774.pub2/references#CD008774-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008774.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008774-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008774-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008774-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008774-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008774-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008774-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008774-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008774\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008774\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008774\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008774\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008774\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008774.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008774.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008774.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008774.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008774.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726622110"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008774.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726622116"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008774.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e98248fc8f3c9',t:'MTc0MDcyNjYyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 